Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
cefazolin + piperacillin + tazobactam
- Development stage
- Unknown
- Lead developer
- Assistance publique - Hôpitaux de Paris
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
cefazolin + piperacillin + tazobactam is a combination antibiotic regimen investigated for the prevention of postoperative infections in patients with severe burns. Cefazolin is a first-generation cephalosporin that provides coverage against Gram-positive cocci, including methicillin-susceptible Staphylococcus aureus (MSSA), by inhibiting bacterial cell wall synthesis through the inactivation of penicillin-binding proteins (PBPs). Piperacillin is an extended-spectrum ureidopenicillin that targets a wide range of Gram-positive and Gram-negative bacteria, as well as anaerobes, also by inhibiting PBPs. Tazobactam is a penicillanic acid sulfone beta-lactamase inhibitor that protects piperacillin from degradation by Class A and Class C beta-lactamases. This combination or the comparative use of these agents has been primarily studied by Assistance Publique - Hôpitaux de Paris in the Phase 3 PROBURN trial to optimize prophylactic antibiotic strategies in the high-risk burn population.
- Other names
- cefazolin/piperacillin/tazobactam
02
Targets
PBP (Penicillin-binding protein family)β-lactamase
Beyond the preview
Go deeper on cefazolin + piperacillin + tazobactam.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on cefazolin + piperacillin + tazobactam.